Manuscripts and Publications

Filters: Author is Wilson, Craig M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, M Fernández I, Rutledge B, Martinez J, Garofalo R et al..  2013.  The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men.. J Acquir Immune Defic Syndr. 62(4):447-56.
Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, E Patton D, Ren W, Thornton SE, Major-Wilson HO, Puga AM et al..  2016.  Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.. J Neurovirol. 22(2):218-30.
Syed SS, Balluz RS, Kabagambe EK, Meyer WA, Lukas S, Wilson CM, Kapogiannis BG, Nachman SA, Sleasman JW.  2013.  Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation.. AIDS Res Hum Retroviruses. 29(3):493-500.
Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2013.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 57(11):5619-28.
B
Arrington-Sanders R, Wilson CM, Perumean-Chaney SE, Patki A, Hosek S.  2019.  Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials.. J Acquir Immune Defic Syndr. 80(2):160-165.
C
Sill AM, Kreisel K, Deeds BGriffin, Wilson CM, Constantine NT, Peralta L.  2007.  Calibration and validation of an oral fluid-based sensitive/less-sensitive assay to distinguish recent from established HIV-1 infections.. J Clin Lab Anal. 21(1):40-5.
Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG et al..  2020.  Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
Li Y, Ni R, Song W, Shao W, Shrestha S, Ahmad S, Cunningham CK, Flynn PM, Kapogiannis BG, Wilson CM et al..  2009.  Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth.. Hum Genet. 126(5):685-96.
Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P et al..  2018.  Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.. Clin Infect Dis. 66(2):213-219.
Lee S, Kapogiannis BG, Flynn PM, Rudy BJ, Bethel J, Ahmad S, Tucker D, Abdalian SEllen, Hoffman D, Wilson CM et al..  2013.  Comprehension of a simplified assent form in a vaccine trial for adolescents.. J Med Ethics. 39(6):410-2.
Neilan AM, Bulteel AJB, Hosek SG, Foote JHA, Freedberg KA, Landovitz RJ, Walensky RP, Resch SC, Kazemian P, A Paltiel D et al..  2021.  Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States.. Clin Infect Dis. 73(7):e1927-e1935.
Gamarel KE, Nichols S, Kahler CW, Westfall AO, Lally MA, Wilson CM.  2018.  A cross-sectional study examining associations between substance use frequency, problematic use and STIs among youth living with HIV.. Sex Transm Infect. 94(4):304-308.
D
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N et al..  2017.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.. Clin Infect Dis. 64(3):317-325.
Sill AM, Constantine NT, Wilson CM, Peralta L.  2010.  Demographic profiles of newly acquired HIV infections among adolescents and young adults in the U.S.. J Adolesc Health. 46(1):93-6.
E
Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng J-H, Gardner EM, Liu A, Glidden DV, Grant R et al..  2016.  Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.. Antimicrob Agents Chemother. 60(11):6692-6697.
Miller RLin, Boyer CB, Chiaramonte D, Lindeman P, Chutuape K, Cooper-Walker B, Kapogiannis BG, Wilson CM, J Fortenberry D.  2017.  Evaluating Testing Strategies for Identifying Youths With HIV Infection and Linking Youths to Biomedical and Other Prevention Services.. JAMA Pediatr. 171(6):532-537.
G
Porter TR, Li X, Stephensen CB, Mulligan K, Rutledge B, Flynn PM, Lujan-Zilbermann J, Hazra R, Wilson CM, Havens PL et al..  2013.  Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: fine-mapping for the GC/DBP gene that encodes the vitamin D-binding protein.. Front Genet. 4:234.
H
Lally MA, van den Berg JJ, Westfall AO, Rudy BJ, Hosek SG, J Fortenberry D, Monte D, Tanney MR, McFarland EJ, Xu J et al..  2018.  HIV Continuum of Care for Youth in the United States.. J Acquir Immune Defic Syndr. 77(1):110-117.
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G et al..  2017.  An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
Turnbull EL, A Lopes R, Jones NA, Cornforth D, Newton P, Aldam D, Pellegrino P, Turner J, Williams I, Wilson CM et al..  2006.  HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently.. J Immunol. 176(10):6130-46.
I
Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G et al..  2015.  Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.. J Acquir Immune Defic Syndr. 69(1):52-60.
Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE.  2013.  Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.. Clin Infect Dis. 57(5):735-44.
Bansal A, Yue L, Conway J, Yusim K, Tang J, Kappes J, Kaslow RA, Wilson CM, Goepfert PA.  2007.  Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.. AIDS. 21(18):2387-97.
J Fortenberry D, Koenig LJ, Kapogiannis BG, Jeffries CL, Ellen JM, Wilson CM.  2017.  Implementation of an Integrated Approach to the National HIV/AIDS Strategy for Improving Human Immunodeficiency Virus Care for Youths.. JAMA Pediatr. 171(7):687-693.
Jaspan HB, Cunningham CK, Tucker TJP, Wright PF, Self SG, Sheets RL, Rogers AS, Bekker L-G, Wilson CM, Duerr A et al..  2008.  Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads.. J Acquir Immune Defic Syndr. 47(1):86-92.
L
Doll M, J Fortenberry D, Roseland D, McAuliff K, Wilson CM, Boyer CB.  2018.  Linking HIV-Negative Youth to Prevention Services in 12 U.S. Cities: Barriers and Facilitators to Implementing the HIV Prevention Continuum.. J Adolesc Health. 62(4):424-433.
Mulligan K, D Harris R, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, Monte D, Sleasman J, Wilson CM, Aldrovandi GM.  2012.  Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.. Clin Infect Dis. 55(3):461-8.
O
Mulligan K, D Harris R, Monte D, Stoszek S, Emmanuel P, Hardin DS, Kapogiannis BG, Worrell C, Meyer WA, Sleasman J et al..  2010.  Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.. Clin Infect Dis. 50(1):106-14.
P
van den Berg JJ, Javanbakht M, Gorbach PM, Rudy BJ, Westfall AO, Wilson CM, Lally MA.  2018.  Partner Notification for Youth Living With HIV in 14 Cities in the United States.. J Acquir Immune Defic Syndr. 77(1):46-52.
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
Kahn JA, Belzer M, Chi X, Lee J, Gaur AH, Mayer K, Martinez J, Futterman DC, Stier EA, Paul ME et al..  2019.  Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.. Papillomavirus Res. 7:52-61.
Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.  2012.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N et al..  2006.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.. J Infect Dis. 194(11):1505-9.
Aaron KJ, Kempf M-C, Christenson RH, Wilson CM, Muntner P, Shrestha S.  2012.  Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.. J Acquir Immune Defic Syndr. 61(4):499-506.
Ludema C, Wilson CM, Lally MA, van den Berg JJ, J Fortenberry D.  2020.  Prior incarceration associated with missed HIV care visits among young people living with HIV in the US.. AIDS Care. 32(9):1150-1154.
R
Cunningham CK, Rudy BJ, Xu J, Bethel J, Kapogiannis BG, Ahmad S, Wilson CM, Flynn PM.  2010.  Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States.. Pediatr Infect Dis J. 29(6):530-4.
Kahana SY, Fernandez MIsabel, Wilson PA, Bauermeister JA, Lee S, Wilson CM, Hightow-Weidman LB.  2015.  Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.. J Acquir Immune Defic Syndr. 68(2):169-77.
Arrington-Sanders R, Wilson CM, Perumean-Chaney SE, Patki A, Hosek S.  2018.  The role of socio-behavioral factors in sub-protective tenofovir diphosphate (TFV-DP) levels among YMSM enrolled in two PrEP trials.. J Acquir Immune Defic Syndr.
S
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, D Harris R, Mulligan K, Zimet G et al..  2017.  Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.
Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB.  2012.  Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.. J Clin Endocrinol Metab. 97(11):4004-13.
Wilson PA, Kahana SY, Fernandez MIsabel, Harper GW, Mayer K, Wilson CM, Hightow-Weidman LB.  2016.  Sexual Risk Behavior Among Virologically Detectable Human Immunodeficiency Virus-Infected Young Men Who Have Sex With Men.. JAMA Pediatr. 170(2):125-31.
Rudy BJ, Sleasman J, Kapogiannis B, Wilson CM, Bethel J, Serchuck L, Ahmad S, Cunningham CK.  2009.  Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.. AIDS Res Hum Retroviruses. 25(6):555-61.
Agwu AL, Bethel J, Hightow-Weidman LB, Sleasman JW, Wilson CM, Rudy B, Kapogiannis BG.  2012.  Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth.. AIDS Patient Care STDS. 26(4):193-6.
T
Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB.  2018.  Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
Gamarel KE, Westfall AO, Lally MA, Hosek S, Wilson CM.  2018.  Tobacco Use and Sustained Viral Suppression in Youth Living with HIV.. AIDS Behav. 22(6):2018-2025.
V
Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM.  2006.  Vitamin D status in adolescents and young adults with HIV infection.. Am J Clin Nutr. 83(5):1135-41.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD et al..  2012.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, D Harris R et al..  2018.  Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.. Clin Infect Dis. 66(2):220-228.